Goldman Sachs Group Inc Roivant Sciences Ltd. Transaction History
Goldman Sachs Group Inc
- $613 Billion
- Q4 2024
A detailed history of Goldman Sachs Group Inc transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 2,108,622 shares of ROIV stock, worth $22.5 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,108,622
Previous 5,392,375
60.9%
Holding current value
$22.5 Million
Previous $62.2 Million
59.92%
% of portfolio
0.0%
Previous 0.01%
Shares
18 transactions
Others Institutions Holding ROIV
# of Institutions
329Shares Held
505MCall Options Held
573KPut Options Held
739K-
Qvt Financial LP New York, NY65.8MShares$703 Million76.3% of portfolio
-
Sb Investment Advisers (Uk) LTD London, X062.1MShares$663 Million6.45% of portfolio
-
Viking Global Investors LP47.8MShares$511 Million1.91% of portfolio
-
Vanguard Group Inc Valley Forge, PA44.1MShares$471 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$378 Million0.01% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $7.52B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...